Multisystem Side Effects of Amiodarone

Rehman, Shahnaz Ul; Siddiqui, Nauman; Khan, Nada Siddique; Raja, Sobia; Assaly, Ragheb

doi:10.1097/maj.0000000000000213

Cited by 9 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Furthermore, numerous adverse side effects are well-known including hyper-and hypothyroidism, QT c prolongation, bradycardia, dermatological reactions, corneal deposits, peripheral neuropathy, as well as lung and liver injury. [5][6][7][8][9][10][11] However, AMIO therapy was shown to decrease the risk of ICD shocks and to reduce arrhythmic end-points in different subgroups. 5,12,13 Prior studies focused on short-term impact of intravenous AMIO therapy and demonstrated decreased rates of life-threatening arrhythmias and ICD shocks.…”

Section: Introductionmentioning

confidence: 99%

Comparable risk of recurrent ventricular tachyarrhythmias in implantable cardioverter‐defibrillator recipients treated with single beta‐blocker or combined amiodarone

Schupp

Behnes

Kim

et al. 2020

Basic Clin Pharma Tox

View full text Add to dashboard Cite

This study sought to assess the prognostic impact of treatment with single beta‐blocker (BB) compared to combined therapy with BB plus amiodarone (BB‐AMIO) on recurrences of ventricular tachyarrhythmias in implantable cardioverter‐defibrillator (ICD) recipients. A large retrospective registry was used including consecutive ICD recipients with index episodes of ventricular tachyarrhythmias from 2002 to 2016. Patients treated with BB were compared to patients treated with BB‐AMIO. Kaplan‐Meier and Cox regression analyses were applied for the evaluation of the primary end‐point defined as first recurrences of ventricular tachyarrhythmias at five years. Secondary end‐points comprised first appropriate ICD therapies, first cardiac rehospitalization and all‐cause mortality at five years. Among 512 ICD recipients, 81% were treated with BB and 19% with BB‐AMIO. BB and BB‐AMIO were associated with comparable risk of first recurrences of ventricular tachyarrhythmias (46% vs. 43%; log rank P = .941; HR = 1.013; 95% CI 0.725‐1.415; P = .941) and appropriate ICD therapies (35% vs. 37%; log rank P = .389; HR = 0.852; 95% CI 0.591‐1.228; P = .390). BB was associated with decreased long‐term all‐cause mortality within an univariable analysis only (20% vs. 28%; log rank p = 0.023). In conclusion, BB and BB‐AMIO were associated with comparable risks regarding recurrences of ventricular tachyarrhythmias at five years.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparable risk of recurrent ventricular tachyarrhythmias in implantable cardioverter‐defibrillator recipients treated with single beta‐blocker or combined amiodarone

Schupp

Behnes

Kim

et al. 2020

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…However, it is associated with a wide variety of side effects that limit its clinical application. Adverse effects include thyroid dysfunction, pulmonary fibrosis, optic neuritis, ataxia, and hepatitis (2–4). Hematologic side effects include bone marrow granulomas, pancytopenia, hemolytic anemia, neutropenia, and thrombocytopenia (5–8).…”

Section: Introductionmentioning

confidence: 99%

Amiodarone-Related Pure Red Cell Aplastic Anemia and Hypothyroidism in a Child With Total Anomalous Pulmonary Venous Connection

Peng

et al. 2019

Front. Pediatr.

View full text Add to dashboard Cite

Introduction: Amiodarone is an effective anti-arrhythmic drug, but there are many clinical side effects that limit its application. There are no case reports of amiodarone-related pure red cell aplastic anemia (PRCA).Case Presentation: Here, we present a case of amiodarone-related PRCA and hypothyroidism in a 7-month-old boy. The patient had a total anomalous pulmonary venous connection (the cardiac type) and had undergone cardiac surgery at the age of 2 months. Eleven days after the operation, atrial tachycardia was observed. Amiodarone was administered orally (15 mg/kg.d), following which the arrhythmia was under control. Subsequently, the patient was prescribed amiodarone (5 mg/kg.d) and discharged. Regular medical consultations were not conducted as required. At 7 months of age (5 months after the operation), the patient returned to the hospital for re-examination. The electrocardiogram showed intermittent sinus bradycardia, occasional junctional escape beats, hemoglobin 7.9 g/DL, and thyroid function—TSH 9.660 uIU/mL.Results: Amiodarone was discontinued. Thyroxine was administered orally. Subsequently, the heart rate improved and TSH returned to normal levels. Nutritional therapy was recommended based on a diagnosis of nutrition-related anemia. A re-visit at 9 months of age showed that the weight was 6 kg, but the routine blood test indicated that hemoglobin was 5.9 g/DL with positive cell anemia and low reticulocyte count. Bone marrow cytology examination suggested PRCA. The hemoglobin level was gradually restored after treatment with prednisone.Conclusion: The use of amiodarone in small infants and young children and its side effects should be carefully monitored. The potential mechanism of amiodarone-related PRCA needs further study.

show abstract

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation

Warraich

Peter

Ahmad

et al. 2020

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Multisystem Side Effects of Amiodarone

Cited by 9 publications

References 1 publication

Comparable risk of recurrent ventricular tachyarrhythmias in implantable cardioverter‐defibrillator recipients treated with single beta‐blocker or combined amiodarone

Comparable risk of recurrent ventricular tachyarrhythmias in implantable cardioverter‐defibrillator recipients treated with single beta‐blocker or combined amiodarone

Amiodarone-Related Pure Red Cell Aplastic Anemia and Hypothyroidism in a Child With Total Anomalous Pulmonary Venous Connection

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation

Contact Info

Product

Resources

About